Bezafibrate

Massachusetts General Hospital tested bezafibrate, a 1970s European lipid drug, as add-on therapy for bipolar depression in a Phase 2 proof-of-concept study (NCT02481245) [1]. The theory: bezafibrate activates PPARs, transcription factors that upregulate mitochondrial fat-burning machinery, and postmortem work has flagged mitochondrial dysfunction as a possible contributor to mood-cycling illness. The trial is now marked completed on ClinicalTrials.gov, but with only 7 patients enrolled against a planned target of 30, which is a recruitment failure on top of a weak design [1]. No follow-on program has materialized, which is the practical answer to whether the sponsor thought the signal was worth chasing. Bezafibrate is marketed as Bezalip and Bezatol SR in Europe and Japan for hyperlipidemia (ATC C10AB02) but was never approved in the US, so any repurposing win in psychiatry would still leave the sponsor without a straightforward US regulatory pathway for the branded product.

Bezafibrate has been an approved lipid-lowering drug in Europe and Japan since the 1970s, sold as Bezalip, Bezatol SR, and generics. It never crossed the FDA finish line in the US, where gemfibrozil and fenofibrate captured the fibrate niche. The MGH bipolar depression trial (NCT02481245) is Phase 2 and now marked completed on ClinicalTrials.gov with an actual enrollment of 7 patients against a planned target of 30 [1]. That is a recruitment failure, not a pilot-by-design, and it means the study never approached the sample size any regulator would consider actionable. The trial was investigator-sponsored, not industry-run, and there is no breakthrough, fast track, orphan, or priority review designation attached. No peer-reviewed readout has surfaced in a major psychiatry journal as of this writing. The commercial reality is that no branded manufacturer is developing bezafibrate for a psychiatric indication and no NDA is filed or planned. On the approved indication side, bezafibrate is still being actively studied in Phase 3 primary biliary cholangitis at Assistance Publique-Hopitaux de Paris (BEZURSO 2, NCT06443606, n=108) as 200 mg or 400 mg add-on to ursodeoxycholic acid, with estimated primary completion December 30, 2027 [2]. That trial reflects where the genuine repurposing energy for bezafibrate sits.

PPARs are transcription factors, meaning they sit inside cell nuclei and switch genes on and off. There are three flavors: PPAR-alpha (mostly liver, controls fat burning), PPAR-gamma (fat cells and insulin sensitivity), and PPAR-delta (muscle and general energy handling). Bezafibrate is one of the few pan-PPAR agonists, hitting all three, whereas most fibrates lean heavily on PPAR-alpha. Turn on PPAR-alpha and cells burn more fatty acids for energy, which is why fibrates lower triglycerides. The bipolar hypothesis rides on a separate observation: neurons in bipolar patients show altered mitochondrial function in postmortem samples, and some rare mitochondrial disorders present with mood symptoms as a feature. If mitochondria are underperforming in mood-relevant circuits, boosting their fatty-acid intake via PPAR activation might restore something. The most relevant precedent is pioglitazone, a PPAR-gamma agonist, which showed higher major-depression remission rates versus control in a meta-analysis (27% vs 10%, PMID 28031713) [6]. That provides partial mechanistic support for the class, and bezafibrate extends the activation across all three PPAR isoforms. The open question is whether broader PPAR activation adds meaningful CNS efficacy or just metabolic noise. Bezafibrate's CNS penetration itself is uncertain: it is highly protein-bound and optimized for hepatic uptake, not brain delivery, so the proposed route to mood effects is probably indirect (normalized fatty-acid metabolism in peripheral tissues lowering systemic inflammatory tone and shifting circulating lipid metabolites that influence neuroinflammation) rather than direct action on brain mitochondria. Indirect mechanisms make the dose-response relationship harder to predict and the expected effect size small. The stronger mechanism-to-outcome link for this drug class sits in cholestatic liver disease, where a 2026 meta-analysis found PPAR agonists reduce pruritus (chronic itch) and improve quality of life in primary biliary cholangitis [3]. That is a validated biology story. The bipolar case is speculative.

NCT02481245 is a small Phase 2 open-label proof-of-concept at MGH, sponsored by the hospital rather than industry [1]. Primary endpoint is change in the Montgomery-Asberg Depression Rating Scale (MADRS) at 8 weeks, a standard clinician-scored depression severity instrument. Secondary endpoints include the Clinical Global Impressions Bipolar Scale and adiponectin as a metabolic biomarker [1]. The study closed with 7 patients enrolled against a planned target of 30, per the ClinicalTrials.gov registry [1]. There is no placebo comparator, no biomarker stratification for enrichment, and no active-drug reference arm. Patients were adults with bipolar depression on stable mood-stabilizing medication, with bezafibrate added on top. An n=7 open-label trial cannot answer whether bezafibrate works for bipolar depression. It can generate a signal worth chasing, or fail to generate one and quietly close. The design is appropriate for a hypothesis-generating academic study but categorically insufficient for regulatory or commercial decisions, and the failure to reach even the modest planned target of 30 adds an operational red flag on top of the design limits. A properly powered Phase 2 would need randomization, placebo control, and roughly 100 or more patients per arm to detect a clinically meaningful MADRS difference against the notoriously high placebo response in depression trials. The absence of a follow-on study from MGH or any pharma partner in the years since enrollment closed is itself a data point.

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk dominates. Bipolar depression has broken most of the drugs thrown at it: SSRIs have modest efficacy and can trigger mania, and only a handful of atypical antipsychotics (quetiapine, lurasidone, cariprazine) plus lithium have durable approvals. Adding a lipid drug to that arena with n=7 open-label data is a very long shot. The mechanistic story about mitochondria is speculative and not backed by human genetics for bipolar disease. Safety risk is real but bounded, because bezafibrate has a decades-long European safety record. Known issues include myopathy (muscle breakdown, especially when combined with statins), rhabdomyolysis (severe muscle-fiber breakdown that can damage the kidneys) in rare cases, and reversible creatinine elevation. In psychiatric patients often on polypharmacy (multiple concurrent medications, standard in bipolar care), drug-drug interactions with mood stabilizers, anticonvulsants, and antipsychotics are a legitimate concern that a proper Phase 3 would need to characterize. Execution risk is high because there is no execution. No industry sponsor, no active follow-on trial, no biomarker strategy to enrich for responders, and the MGH study's failure to hit even a 30-patient target signals recruitment friction that would only get worse in a larger design. The APHP Phase 3 in primary biliary cholangitis (NCT06443606) is the more credible commercial signal for this molecule, but that is a hepatology story, not psychiatry [2]. Commercial risk is total even in the win scenario. Bezafibrate is generic in every market where it is sold, which means no exclusivity to fund a psychiatric label expansion. A method-of-use patent (a patent covering a new indication for an existing drug, as opposed to the molecule itself) on bipolar depression is theoretically possible but hard to enforce against generic off-label use and unlikely to attract capital.

This is noise, not signal, from a commercial-intelligence standpoint. The bipolar depression program is a completed academic pilot with actual n=7 against a planned n=30 and no visible follow-through, functionally equivalent to a negative result even if the raw MADRS numbers were interesting. The interesting bezafibrate story sits in hepatology, not psychiatry. Primary biliary cholangitis (PBC) is an autoimmune disease in which bile acids accumulate and progressively damage bile ducts. PPAR activation suppresses bile-acid synthesis and dampens hepatic inflammation, which is why fibrates work in this context and why the class is now producing approvals. Watch two things. First, NCT06443606 (BEZURSO 2), the APHP-run Phase 3 of bezafibrate 200 mg and 400 mg added to ursodeoxycholic acid in PBC patients with inadequate UDCA response, n=108, with estimated primary completion December 30, 2027 [2]. That readout will determine whether bezafibrate earns a formal role alongside obeticholic acid (Intercept's Ocaliva), seladelpar (Gilead's Livdelzi, PPAR-delta agonist approved 2024), and elafibranor (Ipsen's Iqirvo, PPAR-alpha/delta agonist approved 2024) in the second-line PBC toolkit. Benchmark against seladelpar's approved pruritus data and elafibranor's ELATIVE trial results, since both established PPAR agonists as viable in this space and any bezafibrate positioning will need to beat or complement them on biochemical response, itch, and cost. Second, watch PPAR agonists as a class in PBC pruritus, where a 2026 meta-analysis already flags real effects on itch and quality of life [3]. There is also an ongoing bezafibrate Phase 2 in biliary atresia survivors that showed cholestasis-reducing effects (PMID 41493848) [5]. The bipolar signal would only become worth revisiting if MGH or a collaborator publishes a MADRS effect size clearing the small-CNS-study noise floor, or if a properly powered randomized trial appears in the registry with industry sponsorship. Neither has happened in the years since NCT02481245 closed. Check back on the APHP PBC readout at the end of 2027 for a real inflection. Otherwise, this molecule belongs in the metabolic and cholestatic-liver conversations.